Catalyst
Slingshot members are tracking this event:
FibroGen (FGEN) FG-3019 Phase 2 data on trial evaluating treatment of idiopathic pulmonary fibrosis set for third quarter release in 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| FGEN | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 07, 2017
Occurred Source:
http://investor.fibrogen.com/phoenix.zhtml?c=253783&p=irol-newsArticle&ID=2292360
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 2, Idiopathic Pulmonary Fibrosis, Fg-3019
